Warning lights
Signals from the annual accounts, the CBE and the Official Gazette, each with its threshold and source. No score, no verdict.
-
Negative equity NBB
More debt than assets in 4 of the last 4 fiscal years.
-
Tight liquidity NBB
Cash and receivables cover 2 % of short-term debt in 2025; threshold 65 %.
Financials
Financial year 2025
PHARMA PROJECT from Wavre, company number BE0458257001, closed financial year 2025 with a result of € -11,278 after tax. For that financial year PHARMA PROJECT recorded a gross margin of € 83,959 and equity of € -33,296. Compared with financial year 2024, the result moved from € 1,627 to € -11,278. The company made a loss. More debts than assets. High debts against a small own buffer. The most recent annual accounts were filed with the National Bank of Belgium on January 5, 2026.
€ -33,296
▼ € 11,278 vs 2024
Assets minus debts, by the books. What is left if everything were sold and paid today.
€ -11,278
▼ still € 1,627 profit in 2024
Profit after tax over the fiscal year.
€ 11,865
Cash and bank balances on the last day of the fiscal year.
Loss, nothing to pay out
Reserves fell to € -839,182.
People and assets in 2025
€ 598,272
▼ 10% vs 2024
Of which on lease € 596,181.
Debts at end 2025
€ 461,661
▼ 21% vs 2024
€ 102,889 is repaid this year. At this pace the long-term loan is gone in ≈ 4 years.
€ 9,878
▲ € 8,228 vs 2024
Supplier invoices still open on the last day of the fiscal year.
€ 1,492
▲ 41% vs 2024
Corporate tax and VAT still to pay. No wage debt: nothing outstanding to staff or social security.
Want to see how much further we take a dossier in the Pro version? Open the free De Lijn example and give feedback →
| 2022 | 2023 | 2024 | 2025 | Change 2024 → 2025 | |
|---|---|---|---|---|---|
| Gross margin | € 94,202 | € 89,298 | € 98,259 | € 83,959 | ▼ 15% |
| Profit after taxes | € -11,819 | € -13,986 | € 1,627 | € -11,278 | ▼ € 12,905 |
| Equity | € -9,659 | € -23,645 | € -22,018 | € -33,296 | ▼ € 11,278 |
| Total debts | € 1,021,861 | € 959,956 | € 884,976 | € 839,308 | ▼ 5% |
| Cash | € 4,983 | € 3,079 | - | € 11,865 | |
| Land & buildings | € 208,073 | € 203,213 | € 198,353 | € 193,493 | ▼ 2% |
| Retained profit | € -815,545 | € -829,531 | € -827,904 | € -839,182 | ▼ € 11,278 |
| Bank debt | € 762,550 | € 665,306 | € 585,434 | € 461,661 | ▼ 21% |
| Balance sheet total | € 1,012,202 | € 936,311 | € 862,958 | € 806,013 | ▼ 7% |
Key figures of PHARMA PROJECT, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 30 January 2027.
What happened to PHARMA PROJECT?
What happened at PHARMA PROJECT in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:
- GILLES SMITS stepped down as director. NBB
- JEAN-JACQUES SMITS stepped down as director. NBB
- NICOLE VANSTEENKISTE stepped down as director. NBB
- New annual accounts for financial year 2025: loss of € 11,278 (▼ € 12,905 vs 2024). Source: NBB ↗
- GILLES SMITS became a director. NBB
- JEAN-JACQUES SMITS became a director. NBB
- NICOLE VANSTEENKISTE became a director. NBB
- New establishment in Wavre. KBO
In short
From € 11,819 loss in 2022 to € 11,278 loss in 2025.
Best year ever: 2024, with € 1,627 profit.
A new publication or filing at PHARMA PROJECT? We notify you, reason included.
Follow PHARMA PROJECTDatabakkes Pro
Know what changes at your customers, suppliers and competitors. Without reading an annual account.
- Follow them in one folder Every company in your folder gets this full dossier: household book, all fiscal years, benchmark against companies of the same size.
- We alert you, with the reason New annual account, Official Gazette publication or status change: you get what changed and where it says so.
- In bulk too, and in ChatGPT and Claude Upload your customer list and get the warning signs back per company. Or ask in your own AI assistant, with this register as the source.
Databakkes Pro is being built. Sign up now and you are first in line for an invitation, with a month to try without a credit card.
De Lijn 8 June 2026 New annual account 2025
filed on 8 June 2026
What was left
€ 20 k ▼ 91%
Money in the bank
€ 178 k ▼ 98%
Open the dossier →
NMBS 8 June 2026 New annual account 2025 What was left ▼ 80%
bpost 18 May 2026 New annual account 2025 What was left from loss to profit
Management
Directors
According to the 2025 annual accounts
GILLES SMITS
Director
Also active at: Wavrienne de Gestion Immobilière, HG IMMO, HG Pharma, Pharmacie Smits Basse Wavre, PHARMACIE SMITS
since 2020 · until 2026
JEAN-JACQUES SMITS
Managing director
Also active at: PLANT SUN, PHARMACIE SMITS ECHT, Pharma Project II, PHARMACIE SMITS ZONING NORD, PHARMACIE SMITS
since 2020 · until 2026
since 2020 · until 2026
Establishments
Establishment units
Physical locations of this company
Place Cardinal Mercier 6
1300 Wavre
Who else lives here?
A building full of entrepreneurs or one very busy letterbox? Another 4 companies are registered at this address.
All companies at this address →What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.
Details
- Company number
- 0458.257.001
- VAT number
- BE 0458.257.001
- Registered office
- Place Cardinal Mercier 6, 1300 Wavre
- Names & denominations
- PHARMA PROJECT
- Enterprise type
- Rechtspersoon
- Legal form
- Public limited company
- Legal situation
- Normale toestand
- Start date
- 19 June 1996
- Peppol
- Active · Active since 4 May 2026